These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 22579861)
1. New technologies for new influenza vaccines. Shaw A Vaccine; 2012 Jul; 30(33):4927-33. PubMed ID: 22579861 [TBL] [Abstract][Full Text] [Related]
2. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Wei HJ; Chang W; Lin SC; Liu WC; Chang DK; Chong P; Wu SC Vaccine; 2011 Sep; 29(41):7163-72. PubMed ID: 21651946 [TBL] [Abstract][Full Text] [Related]
3. Bringing influenza vaccines into the 21st century. Settembre EC; Dormitzer PR; Rappuoli R Hum Vaccin Immunother; 2014; 10(3):600-4. PubMed ID: 24378716 [TBL] [Abstract][Full Text] [Related]
4. MDCK cell-cultured influenza virus vaccine protects mice from lethal challenge with different influenza viruses. Liu K; Yao Z; Zhang L; Li J; Xing L; Wang X Appl Microbiol Biotechnol; 2012 Jun; 94(5):1173-9. PubMed ID: 22415544 [TBL] [Abstract][Full Text] [Related]
8. Terrapinn's world influenza congress Europe 2009. Part 2. Veryard C IDrugs; 2010 Feb; 13(2):78-9. PubMed ID: 20127556 [TBL] [Abstract][Full Text] [Related]
9. Development and strategies of cell-culture technology for influenza vaccine. Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703 [TBL] [Abstract][Full Text] [Related]
11. The influenza vaccine innovation system and lessons for PDPs. Huzair F Hum Vaccin Immunother; 2012 Mar; 8(3):407-10. PubMed ID: 22327495 [TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccines in plants. Giorgi C; Franconi R; Rybicki EP Expert Rev Vaccines; 2010 Aug; 9(8):913-24. PubMed ID: 20673013 [TBL] [Abstract][Full Text] [Related]
13. Innovative vaccine production technologies: the evolution and value of vaccine production technologies. Bae K; Choi J; Jang Y; Ahn S; Hur B Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962 [TBL] [Abstract][Full Text] [Related]
14. The development and manufacture of influenza vaccines. Buckland BC Hum Vaccin Immunother; 2015; 11(6):1357-60. PubMed ID: 25844949 [TBL] [Abstract][Full Text] [Related]
15. Application of new vaccine technologies for the control of transboundary diseases. Swayne DE Dev Biol (Basel); 2004; 119():219-28. PubMed ID: 15742632 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791 [TBL] [Abstract][Full Text] [Related]
17. Vaccine process technology. Josefsberg JO; Buckland B Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777 [TBL] [Abstract][Full Text] [Related]
18. Using plant cells as influenza vaccine substrates. Chichester JA; Haaheim LR; Yusibov V Expert Rev Vaccines; 2009 Apr; 8(4):493-8. PubMed ID: 19348564 [TBL] [Abstract][Full Text] [Related]
19. Cell culture–derived influenza vaccines: has their time come? Bernstein DI Clin Infect Dis; 2010 Nov; 51(9):1005-6. PubMed ID: 20868285 [No Abstract] [Full Text] [Related]
20. Vaccine manufacturing: challenges and solutions. Ulmer JB; Valley U; Rappuoli R Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]